ZA200104322B - Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group. - Google Patents

Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group. Download PDF

Info

Publication number
ZA200104322B
ZA200104322B ZA200104322A ZA200104322A ZA200104322B ZA 200104322 B ZA200104322 B ZA 200104322B ZA 200104322 A ZA200104322 A ZA 200104322A ZA 200104322 A ZA200104322 A ZA 200104322A ZA 200104322 B ZA200104322 B ZA 200104322B
Authority
ZA
South Africa
Prior art keywords
carbon atoms
phenyl
alkyl
hydrogen
chloro
Prior art date
Application number
ZA200104322A
Inventor
Jonathan David Bloom
Martin Joseph Digrandi
Jones Thomas Richard
Adma Antonia Ross
O'hara Bryan Mark
Kevin Joseph Curran
Russel George Dushin
Stanley Albert Lang
Eugene Anthony Terefenko
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200104322B publication Critical patent/ZA200104322B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/20—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Description

HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA
INHIBITORS OF HERPES VIRUSES CONTAINING A SUBSTITUTED
PHENYLENEDIAMINE GROUP
Background of the Invention
Eight viruses have been identified which are members of the family
Herpesviridae (reviewed in Roizman, B. 1996. Herpesviridae, p. 2221-2230. In B. N.
Fields, D. M. Knipe, and P. M. Howley (ed.), Fields Virology, 3rd ed. Lippincott-
Raven Publishers, Philadelphia, PA). Each member of this family is characterized by an enveloped virus containing proteinaceous tegument and nucleocapsid, the latter of which houses the viruses’ relatively large double-stranded DNA genome (i.e. approximately 80-250 kilobases). Members of the human alphaherpesvirus subfamily are neurotropic and include herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), and varicella-zoster virus (VZV). The human betaherpesviruses are cytomegalovirus (HCMYV), human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7). The gammaherpesviruses are lymphotropic and include Epstein-Barr virus (EBV) and Kaposi's herpesvirus (HHV-8). Each of these herpesviruses is causally- related to human disease, including herpes labialis and herpes genitalis (HSV-1 and
HSV-2 [Whitley, R.J. 1996. Herpes Simplex Viruses, p. 2297-2342. In B. N. Fields,
D. M. Knipe, and P. M. Howley (ed.), Fields Virology, 3rd ed. Lippincott-Raven
Publishers, Philadelphia, PA]); chicken pox and shingles (VZV [Arvin, A. 1996.
Varicella-Zoster Virus, p. 2547-2585. In B. N. Fields, D. M. Knipe, and P. M.
Howley (ed.), Fields Virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia,
PA}; infectious mononucleosis (EBV [Rickinson, A. B. and Kieff, E. 1996. Epstein-
Barr Virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.),
Fields Virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PAJ}); pneumonia and retinitis (HCMV [(Britt, W. J, and Alford, C. A. 1996.
Cytomegalovirus, p. 2493-2523. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed), Fields Virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA}); exanthem subitum (HHV-6 [(Pellet, P. E, and Black. J. B. 1996. Human Herpesvirus 6, p. 2587-2608. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields
Virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA] and HHV-7 [Frenkel. N., and Roffman, E. 1996. Human Herpesvirus 7, p. 2609-2622. In B. N.
Fields, D. M. Knipe, and P. M. Howley (ed.), Fields Virology, 3rd ed. Lippincott-
Raven Publishers, Philadelphia, PA]); and Kaposi's sarcoma (HHV-8 [Neipel, F.,
Albrecht, J.C, and Fleckenstein, B. 1997. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus &: determinants of its pathogenicity? J. Virol. 71:4187-92, 1997}). HCMV is considered in more detail below. Following the primary infection, herpesviruses establish latency within the infected individual and remain there for the remainder of his/her life. Periodic reactivation of latent virus is clinically relevant. In the case of HSV, reactivated virus can be transmitted to infants during birth, causing either skin or cye infection, central nervous system infection, or disseminated infection (i.e. multiple organs or systems). Shingles is the clinical manifestation of VZV reactivation. Treatment of
HSV and VZV is generally with antiviral drugs such as acyclovir (Glaxo Wellcome), } ganciclovir (Roche) and foscarnct (Asta) which target viral encoded DNA polymerase.
HCMYV is a ubiguitous opportunistic pathogen inieciing 50-90% of the aduit population (Britt, W. I, and Alford, C. A. 1996. Cytomegalovirus, p. 2493-2523. In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields Virology, 3rd cd.
Lippincott-Raven Publishers, Philadelphia, Pa.). Primary infection with HCMV is usually asymptomatic, although heterophile negative mononucleosis has been observed. The virus is horizontally transmitted by sexual contact, breast milk, and saliva. Intrauterine transmission of HCMV from the pregnant mother to the fetus occurs and is often the cause of serious clinical consequences. HCMV remains in a latent state within the infected person for the remainder of his/her life. Cell-mediated immunity plays a central role in controlling reactivation from latency. Impaired cellular immunity leads to reactivation of latent HCMV in seropositive persons.
HCMV disease is associated with deficient or immature cellular immunity.
There are 3 major categories of persons with HCMV discase (reviewed by Britt and
Alford, 1996). (1) In immunocompromised (AIDS) patients, HCMYV is one of the two most common pathogens causing clinical disease (the other is Pneumocystis). .
The most common manifestation of HCMV in AIDS is retinitis, although infection of other organs including the adrenal glands, lungs, GI tract, and central nervous system are also reported frequently. 90% of AlIDs patients have active HCMV infection; 25- 40% (~85,000 patients in the United States) have life- or sight-threatening HCMV disease. HCMV is the cause of death in 10% of persons with AIDs. (2) Due to immune system suppression to reduce the risk of graft rejection, HCMV reactivation or reinfection is common amongst kidney, liver, heart, and allogeneic bone marrow transplant patients. Pneumonia is the most common HCMV disease in these patients, occurring in up to 70% of these transplant patients. (3) Congenital infection due to
HCMV occurs in 1% of all births, about 40K per year. Up to 25% of these infants are symptomatic for HCMV disease between ages 0-3 years. HCMV disease is progressive, causing mental retardation and neurological abnormalities, in children.
Recent studies suggest that treatment with anti-HCMV drugs may reduce morbidity . in these children.
Several antiviral drugs are currently being marketed (Bron, D., R. Snoeck, and L. Lagneaux. 1996. New insights into the pathogenesis and treatment of cytomegalovirus. Exp. Opin. Invest. Drugs 5:337-344; Crumpacker, C. 1996.
Ganciclovir. New Eng. J. Med. 335:721-729; Sachs, S., and F. Alrabiah. 1996. Novel herpes treatments: a review. Exp. Opin. Invest. Drugs 5:169-183). These include: ganciclovir (Roche), a nucleoside analog with hemopoietic cell toxicity; foscarnet (Astra), a pyrophosphate analog with nephrotoxicity; and cidofovir, Gilead), a nucleoside phosphonate with acute nephrotoxicity. Each of these drugs target the viral-encoded DNA polymerase, are typically administered intravenously due to their low bioavailability, and, as noted above, are the source of significant toxicity.
Ganciclovir-resistant mutants which arise clinically are often cross-resistant with cidofovir. Hence, there is a need for safer (i.c. less toxic), orally bioavailable anti- viral drugs which are directed against novel viral targets.
Phenyl thioureas are disclosed for use in a variety of pharmaceutical applications. Armistead, et al., WO 97/40028, teaches phenyl ureas and thioureas as inhibitors of the inosine monophosphate dehydrogenase (IMPDH) enzyme which is taught to play a role in viral replication diseases such herpes.
Widdowson, ¢t al., WO 96/25157, teaches phenyl urea and thiourea compounds of thc below formula for treating diseases mediated by the chemokine, interleukin-8.
LU om AL "
NY
Morin, Jr., et al, U.S. Patent No. 5,593,993 teaches certain phenyl thiourea compounds for treatment of AIDs and the inhibition of the replication of HIV and related viruses.
Therefore, it is an object of this invention to provide compounds, and pharmaceutically acceptable salts thereof, to inhibit and/or treat diseases associated with herpes viruses including human cytomegalovirus, herpes simplex viruses,
Epstein-Barr virus, varicella-zoster virus, human herpesviruses-6 and -7, and Kaposi herpesvirus.
Description of the Invention :
In accordance with the present invention are provided compounds having the formula:
Rs 5 Ro 10 ig SEE Bg, GE oo 20 0 RR Ry Riz 1 wherein
R,-R, are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 carbon members, aryl. heteroaryl, halogen, -CN, -NO,, -CO,R,, -COR,, -OR,, -SR, -SOR, -SO,R,,
-CONRR,, -NR,N(R,R,), -N(R,R,) or W-Y-(CH,) -Z provided that at least one of R-R; is not hydrogen; or R, and R; or R, and R,, taken together form a 3 to 7 membered heterocycloalkyl or 3 to 7 membered heteroaryl;
R, and R, are independently hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, or aryl;
R, is hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 members, aryl or heteroaryl, or
R, and R,, taken together may form a 3 to 7 membered heterocycloalkyl;
R,-R , are independently hydrogen, alkyl of 1 to 4 carbon atoms, perhaloalkyl of 1 to 4 carbon atoms, halogen, alkoxy of 1 to 4 carbon atoms, or cyano, or R; and R, or R,, and R, may be taken together to form aryl of 5 to 7 carbon atoms; provided that at least one of R, , is not hydrogen;
Wis O, NR,, or is absent;
Y is -(CO)- or -(CO,)-, or is absent;
Z is alkyl of 1 to 4 carbon atoms, -CN, -COR,, COR, -CONRR,, -OCOR,, -NR,COR,, -OCONR,, -OR,, -SR,, -SOR,, -SO,R,, SRN(R.R)), -N(R,R,) or phenyl;
G is a monocyclic heteroaryl;
X is a bond, -NH, alkyl of 1 to 6 carbon atoms, alkenyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, thioalkyl of 1 to 6 carbon atoms, alkylamino of 1 to 6 carbon atoms, or (CH)J;
J is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or benzyl; and nisl t6, or pharmaceutical salts thereof.
In some preferred embodiments of the present invention at least one of R,-R, is not hydrogen. In other preferred embodiments of the present invention, R-R; are independently, hydrogen alkyl of 1 to 6 carbon atoms, halogen, perhaloaikyl of 1 to 6 carbon atoms, OR, or N(R R,). Preferably, 1 to 3 of R,-R, is not hydrogen. Most preferably, 2 of R-R, 1s not hydrogen. In preferred compounds of the present invention R, and R,. or R, and R, are preferably, independently, halogen or CF.
In some preferred embodiments of the present R9-R12 are selected from halogen, methyl, methoxy and cyano.
In some embodiments of the present invention G is preferably thiazolyl, thiadiazolyl, oxazolyl or furyl. More preferably G is furan. G is preferably not substituted.
In some embodiments of the present invention X is a bond or C1-C4 alkyl.
Preferably, when X is C1-C4 alkyl, said alkyl is straight chain alkyl.
Preferred compounds of the present invention are the following compounds which include pharmaceutical salts thereof:
Furan-2-carboxylic acid {4-{3-(5-chloro-2,4-dimethoxy-phenyi)-thioureido]- 2,5-dimethoxy-phenyl }-amide,
Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- : 3-trifluoromethyl-phenyl}-amide,
Furan-2-carboxylic acid {3-chloro-4-[3-(5-chloro-2,4-dimethoxy-phenyl)- thioureido}-phenyl }-amide,
Furan-2-carboxylic acid {5 chloro-4-{3-(5-chloro-2,4-dimethoxy-phenyl)- thioureido]-2-mcthyl-phenyl }-amide,
Furan-2-carboxylic acid {5-chioro-4-[3-(5-chioro-Z.4-dimethoxy-phenyl)- thioureido}-2-hydroxy-phenyl }-amide,
Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 3-cyano-phenyl }-amide,
Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido}- ] 25 __3-methyl-phenyl}-amide, — ee =
Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 2-methoxy-5-methyl-phenyl }-amide,
Furan-2-carboxylic acid {4-{3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido}- ] 3-methoxy-phenyl }-amide,
Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thiourcido]- 2-trifluoromethyl-phenyl}-amide,
Furan-2-carboxylic acid {2-chloro-4-[3-(5-chloro-2,4-dimcthoxy-phenyl)- thioureido]-phenyl }-amide,
Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 2-cyano-phenyl }-amide, 5-[3-(5-Chloro-2,4-dimethoxy-phenyl)-thioureido]-2-[(furan-2-carbonyl)- amino]-benzoic acid,
Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 2-phenylcarbamoyl-phenyl }-amide,
Furan-2-carboxylic acid {2-benzoy}-4-[3-(5-chloro-2,4-dimethoxy-phenyl)- thioureido]-phenyl }-amide,
Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 2-methyl-phenyl}-amide,
Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- naphthalen-1-yl }-amide; and
Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 2-methoxy-phenyl }-amide, and pharmaceutical salts thereof.
Alkyl as used herein refers to straight or branched chain lower alkyl of 1 to 6 carbon atoms. Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.
Alkenyl as used herein refers to straight or branched chain lower alkyl of 2 to 6 carbon atoms containing at least one carbon-carbon double bond. Alkenyl includes vinyl groups.
Alkynyl as used herein refers to straight or branched chain lower alkyl of 2 to 6 carbon atoms containing at least one carbon-carbon triple bond.
Alkyl, alkenyl and alkynyl groups of the present invention may be substituted or unsubstituted.
Cycloalkyl refers to a saturated mono or bicyclic ring system of 3 to 10 carbon atoms. Exemplary cycloalkyl groups include cyclopentyl, cyclohexyl and cycloheptyl. Cycloalkyl groups of the present invention may be substituted or unsubstituted.
Heterocycloalkyl refers to a saturated mono or bicyclic ring system of 3 to 10 members having | to 3 heteroatoms selected from N, S and O, including, but not limited to aziridinyl, azetidinyl, imidazolidinyl, morpholinyl, thiomorpholinyl,
piperazinyl, pyrazolidinyl, piperidinyl, and pyrrolidinyl. Heterocycloalkyl groups of the present invention may be substituted or unsubstituted.
Aryl, as used herein refers to an aromatic mono or bicyclic ring of 5 to 10 carbon atoms. Exemplary aryl groups include phenyl, naphthyl, and biphenyl. Aryl groups of the present invention may be substituted or unsubstituted.
Heteroaryl as used herein refers to an aromatic mono or bicyclic ring of 5 to members having 1 to 3 heteroatoms selected from N, S or O including. but not limited to thiazolyl, thiadiazolyl, oxazoly}, {uryl, indolyl, benzothiazolyl, benzotriazolyl, benzodioxyl, indazolyl, and benzofuryl. Preferred heteroaryls include 10 quinolyl, isoquinolyl, napthalenyl, benzofuranyl, benzothienyl, indolyl, pyridyl, pyrazinyl, thienyl, furyl, pyrrolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, pyrazolyi, triazolyl, thiadiazolyl, and imidazolyl. Heteroaryl groups of the present invention may be substituted or unsubstituted.
Perhaloalkyl refers to an alkyl group of 1 to 6 carbon atoms in which three or more hydrogens are substituted with halogen.
Phenyl as used herein refers to a 6 membered aromatic ring.
Halogen, as used herein refers to chlorine, bromine, iodine and fluorine.
Unless otherwise limited substitutents are unsubstituted and may include alkyl of 1 10 6 carbon atoms, cycloalkyl! of 110 6 carbon atoms, heterocycloalkyl of ito 6 members, perhaloalkyl of 1 to 6 carbon atoms, alkylamino, dialkylamino, aryl or heteroaryl.
Carbon number refers to the number of carbons in the carbon backbone and does not include carbon atoms occurring in substituents such as an alkyl or alkoxy substituents. — - 25 + - Whereterms are used in combination, the definition for each individual part of the combination applies unless defined otherwise. For instance, alkylcycloalkyl is an alkyl-cycloalkyl group in which alkyl and cycloalkyl are as previously described.
Pharmaceutically acceptable salts are the acid addition salts which can be formed from a compound of the above gencral formula and a pharmaceutically acceptable acid such as phosphoric, sulfuric, hydrochloric, hydrobromic, citric, maleic, succinic, fumaric, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid, and the like.
The compounds of this invention contain a chiral center, providing for various seteroisomeric forms of the compounds such as racemic mixtures as well as the individual optical isomers. In some preferred embodiments of the present invention the compounds of the present invention are substantially pure optical isomers. By substantially purc is meant the composition contains greater than 75% of the desired isomer and may include no more than 25% of the undesired isomer. In more preferred embodiments the pure optical isomer is greater than 90% of the desired isomer. In some preferred emodiments, when the target is VZV, the (S) isomer is preferred. The individual isomers can be prepared directly or by asymmetric or stereospecific synthesis or by conventional separation of optical isomers from thc racemic mixture.
Compounds of the present invention may be prepared by those skilled in the art of organic synthesis employing methods described below which utilize readily available reagents and starting materials unless otherwise described. Compounds of the present invention are thus prepared in accordance with the following schemes. : The novel compounds of the present invention are prepared according to the following reaction schemes.
Referring to Methods 31 and 34, reacting appropriately substituted amines 2, wherein the substitutents R -R,, and X are described as above, with appropriately substituted isothiocyanates 3, wherein the substituents R-R,, and G are described above, either neat or in an appropriate solvent such as tetrahydrofuran, acetonitrile, ethyl acetate, dichloromethane, or N,N-dimethylformamide affords the desired thioureas 1. Similarly, reaction of appropriately substituted isothiocyanates 4, wherein the substitutents R -R;, and X are described as above with appropriately substituted anilines 5, wherein the substituents R,-R, and G are described above, in a convenient solvent such as those listed above affords the desired thioureas 1.
Methods 31 and 34
R 5 R 10 0
R3 NH, + S&S=C= CG
R, R, 1 R, 2 2 3 AN
A Ry . ; R 10 :
Rs X—N—C— NW-C—G
H rH 4
Rx Ry Ry R12 1
Ry ¢ R ‘0 _ =\ f
Yani vets
Re Ri Ris R12 4 5 5 Alternatively. appropriately substituted thioureas 1 can be prepared as described by Methods 32 and 33 by reacting amines 2 and 5, wherein R-R;, R-R, and G are described as above, in the presence of either one molar equivalent of 1,1°- thiocarbonyi diimidazole in an appropriate solvent such as dichloro-methane and tetrahydrofuran or mixtures thereof or one molar equivalent of 1,1’-thiocarbonyl-di- (1,2,4)-triazole in an appropriate solvent such as dichloromethane and tetrahydrofuran or mixtures thereof at room temperature. - - Methods 32,33 -
H, x (ee (a0) = 2) ANH, NN
Z H H
NH, 1) CS(Triaz), my s 2 43
E— 2) AtNH, CA,
H H
In certain instances, subsequent chemical modification of the final thiourcas 1 was required. These methods, Methods 35-39, are summarized below. (DJA Oe 23 =
FZ NTN EtOH Z N
De H H p H H
OAc OH
QAO = O10 -
ZN EtOH ASN 3 H H 3 H H
BGC HOOC
(21 = iq = AA =
N
2 NN NON
OH OBz
DJ 02 33 = : =
NN AEN
2 H 2 H H
OH OMs
DW we ae A 39 b N WN D NN
OMs NR, ’
SnCh x
IQ Em (3D)
N” SN MeOH ata
H H H H
Na NH,
Thioureas 1 wherein at least one substituent of R -R, is 1-hydroxyethoxy or carboxy-methoxy, R,-R,, and G are defined as above and X equals a bond, may be prepared from the corresponding alkyl esters by alkaline hydrolysis with aqueous sodium or potassium hydroxide in a suitable solvent such as methanol, tetrahydro- furan or mixtures thereof at room temperature in accordance with Methods 35 and
Thioureas 1 wherein at least one substituent of R-R; is 1-acyloxyethoxy or methansulfonoxyethoxy, R -R , and G are defined as above and X equals a bond, may be prepared from the corresponding I-hydroxyethoxy derivative by acylation with appropriate acylating agents such as benzoic acid chloride or methanesulfonic acid chloride in the presence of a suitable tertiary amine base such as triethylamine or diisopropylethylamine in a suitable solvent such as dichloromethane or the like at room temperature in accordance with Methods 37 and 38. : Thioureas 1 wherein at least one substituent of R,-R, is 1-aminoethoxy, R,-R,, and G are defined as above and X equals a bond, may be prepared from the corresponding 1-methanesulfonoxy-ethoxy derivative by reaction with an appropriate secondary amine such as dimethylamine in a suitable solvent mixture such as tetrahydrofuran and water or the like at room temperature in accordance with Method 39.
Thioureas 1 wherein at least one substituent of R -R; is 1-aminoalkyl, R,-R,, and G arc defined as above and X equals a bond, may be prepared from the corresponding 1-azidoaikyi derivative by reaction with stannous chioride in a suitable solvent such as methanol, ethanol or the like at room temperature in accordance with
Method 40.
The intermediate isothiocyanates 3 and 4 shown above in Methods 31 and 34 are prepared in accordance with Method 41 (below) essentially according to the procedures of Staab, H.A. and Walther, G. Justus Liebigs Ann. Chem. 657, 104 oo ) 25_ (1962) by reacting appropriately substituted amines 5 or 2, respectively, wherein R -
R,, R,-R,, and G are described above and X is defined above, with one molar equivalent of 1,1’-thiocarbonyldiimidazole in an appropriate solvent such as dichloromethane and tetrahydrofuran or mixtures thereof.
Method 41
IN=\ y
EN
? : i Q
H, N—CG ——> S=C=N N—c—G
H H
3
N=\
Rg 5 (Cy Ry 5 2
R, R; R, Ry 2 4 5 The intermediates 2 and 5 may be prepared according to the following protocols:
According to Methods 1A-1G, amines 2, wherein R -R, arc defined above and
X is defined above and amines 5, wherein R,-R , are defined above, may be prepared by reduction of the appropriately substituted nitrobenzenes according to a variety of procedures known to those skilled in the art and described in R. J. Lindsay,
Comprehensive Organic Chemistry (ed. Sutherland), Volume 2, Chapter 6.3.1,
Aromatic Amines, 1979. Such procedures include the reduction of nitrobenzenes to form anilines upon exposure to: a) iron powder and a strong acid, such as hydrochloric acid (Methods 1A) either neat or in alcohol solvent such as methanol or ethanol, at temperatures ranging from room temperature to the refluxing temperature of the solvent, or; b) iron powder and glacial acetic acid (Method 1B), either neat or in alcohol solvent such as methanol or cthanol, at temperatures ranging from room temperature to the refluxing temperature of the solvent, or;
¢) iron powder and aqueous ammonium chloride (Method 1C), cither neat or in alcohol solvent such as methanol or cthanol, at temperatures ranging from room temperature to the refluxing temperature of the solvent, or; d) tin and a strong mineral acid, such as hydrochloric acid (Method 1D), either neat or in alcohol solvent such as methanol or ethanol, at temperatures ranging from room temperature to the refluxing temperature of the solvent, or; e) when R-R, and R-R , are selected from Cl, Br, I, -(OSO,)-CF,, or -(0OSO,)-1-(4- methylphenyl), by catalytic reduction such as with hydrogen and palladium on carbon (Method 1E) in an appropriate solvent such as methanol, ethanol, or ethyl acetate, under one or more atmospheres of pressure or; f) when R-R, and R-R , are selected from Cl, Br, I, -(0S0O,)-CF,, or -(0SO,)-1-(4- methylphenyl), by catalytic reduction such as with cyclohexene and palladium on : carbon (Method 1F) in an appropriate solvent such as methanol or ethanol, at temperatures ranging from room temperature to the refluxing temperature of the solvent, or; 2) aqueous sodium hydrosulfite in alcohol solvent at temperatures ranging from room temperature to the refluxing temperature of the solvent (Method 1G).
Alternatively, according to Methods 3A-3C, amines 2. wherein R-R, are defined above and X is defined above and anilines 5, wherein R-R , are defined above, may be prepared by the cleavage of the aniline nitrogen-carbon bond of amide and carbamate derivatives of these anilines according to a variety of procedures known to those skilled in the art and described in Greene, Protective Groups in
Organic Synthesis volume 2, Chapter 7, 1991, and references therein. Such i 25 procedures include: ] _ B a) the exposure of appropriately substituted arylamino-tert-butyl-carbamates to a strong acid such as trifluoroacetic acid (Method 3A)either neat or in an appropriate solvent such as dichloromethane at temperatures between (°C and room temperature, or; b) the exposure of appropriately substituted arylamino-(2-trimethylsilylethyl)- carbamates to a fluoride ion source such as tetrabutylammonium fluoride or potassium fluoride (Method 3B) in aqueous acetonitrile or tetrahydrofuran or mixtures thereof at temperatures ranging from room temperature to the reflux temperature of the solvent, or; ¢) the exposure of appropriately substituted arylamino-trifluoroacetamides to a strong base such as sodium or potassium hydroxide or sodium or potassium carbonate in an alcohol solvent such as methanol or ethanol (Method 3C) at temperatures ranging from room temperature to the reflux temperature of the solvent.
Alternatively, according to Method 11, amines 2, wherein R -R, are defined above, and X is defined above and at least one substituent of R-R; is defined as vinyl, may be prepared by the palladium catalyzed coupling of a vinyl trialkyltin reagent, such as tributylvinyltin, with an appropriately substituted bromo- or iodo- aniline, for example 3-chloro-4-iodo-aniline, employing a palladium catalyst, such as tris(dibenzylidineacetone)-bipalladium, and a ligand, such as triphenylarsine, in a suitable solvent such as tetrahydrofuran or N-methylpyrrolidinone, at temperatures ranging from room temperature to the reflux temperature of the solvent, essentially according to the procedures of V. Farina and G.P. Roth in Advances in Metal-
Organic Chemistry, Vol. 5, 1-53, 1996 and references therein.
Alternatively, according to Method 42, amines 2, wherein R-R, are defined above and X equals a bond and at least one substituent of R, or R, is defined as dialkylamino, may be prepared by the palladium catalyzed amination of an appropriately substituted 3- or 5-bromo- or iodo-aniline, for example 3-amino-5- bromobenzotrifluoride, by secondary amines under conditions which employ a palladium catalyst, such as bis(dibenzylidineacetone)palladium, and a ligand, such as tri-o-tolylphosphine, and at least two molar equivalents of a strong base, such as lithium bis-(trimethylsilyl)amide in a sealed tube, in a suitable solvent such as tetrahydrofuran or toluene, at temperatures ranging from room temperature to 100°C, essentially according to the procedures of JF. Hartwig and J. Louic Tetrahedron
Letters 36 (21), 3609 (1995).
Alternatively, according to Method 43, amines 2, wherein R-R; are defined above and X is defined above and at least one substituent of R, or R, is defined as alkyl, may be prepared by the palladium catalyzed alkylation of an appropriately substituted 3- or 5-bromo-or iodo-aniline, for example 3-amino-5- bromobenzotrifluoride by alkenes under condiditons which employ a palladium catalyst such as [1,1’-bis(diphenylphosphino)ferrocene]palladium (I) chloride-
dichloromethane complex and in the presence of 9-borabicyclo[3.3.1]nonane and a suitable base such as aqueous sodium hydroxide in a suitable solvent such as tetrahydrofuran or the like at temperatures ranging from room temperature to the reflux temperature of the solvent.
The acyl and carbamoyl amine derivatives utilized as starting materials in
Methods 3A-3C may be prepared by the derivatization of the corresponding amines : as described in Methods 2A-2G according to a variety of procedures known to those skilled in the art and described in Greene, Protective Groups in Organic Synthesis volume 2, Chapter 7, 1991, and references therein. Such procedures include: a) the reaction of an appropriately substituted amine with di-tert-butyl-dicarbonate (Method 2A) in the presence or absence of one or more molar equivalents of a tertiary amine such as triethylamine or N,N-diisopropylethylamine in a suitable solvent such as acetone, tetrahydrofuran, dimethylformamide, dichloromethane, and the like, at temperatures ‘ranging from room temperature to the reflux temperature of the solvent to produce the corresponding arylamino-tert-butyl- . carbamate, or; b) the reaction of an appropriately substituted aniline with 1-[2-(trimethyl- silyl)ethoxycarbonyi-oxyjbenzotriazole (Method 2B) in the presence of a tertiary amine such as triethylamine or diisopropylethylamine in a suitable solvent such as dimethylformamide at room temperature to produce the corresponding arylamino- (2-trimethyisilylethyl)-carbamate, or; c) the reaction of an appropriately substituted aniline with a carboxylic acid chloride : or acid anhydride (Method 2C) either neat or in an appropriate solvent such as tetrahydrofuran, dimethylformamide, dichloromethane, pyridine and the like, in — 25 the presence of one or more molar equivalents of a teriary amine base such as triethylamine or N,N-diisopropylethyl-amine to produce the corresponding arylaminoamide, or; d) the reaction of an apptopriately substituted nitro aniline with a carboxylic acid chloride (Method 2D) in the absence of one or more molar equivalents of a teriary amine base such as triethylamine or N,N-diisopropylethylamine either neat or in an appropriate solvent such as tetrahydrofuran, 1,4-dioxane and the like at temperatures ranging from room temperature to the reflux temperature of the solvent to produce the corresponding nitro arylaminoamide, or;
e) the reaction of an appropiately substituted aniline with a carboxylic acid (Method 2E) in the presence of a coupling agent such as benzotriazole-1-yloxy-tris- (dimethylamino)-phosphonium hexafluorophosphate, 2-(1H-benzotriazole-1-yl- 0xy)-1,1,3,3-tetra-methyluronium hexafluorophosphate, dicyclohexyl carbodi- imide and the like and in the presence of a tertiary amine such as triethylamine or diisopropylethylamine in a suitable solvent such as diichloromethane, dimethylformamide and the like, at room temperature to produce the corresponding arylaminoamide, or; f) the reaction of an appropriately protected aniline such as an arylamino-tert-butyl- carbamate or the like in which at least one substituent of R,-R,, is defined as -W-Y-(CH,),-Z wherein W, Y, and Z are defined as above, with a carboxylic acid anhydride (Method 2F) in the presence of a suitable base such as pyridine in an appropriate such as dichloromethane, dimethylformamide or the like at ) temperatures ranging from 0°C to room temperature to produce the corresponding carboxylic acid ester, or; : g) the reaction of an appropriately substituted aniline in which a t least one substituent of R -R; is defined as hydroxyl with di-tert-butyl-dicarbonate (Method 2G) in the absence of one or more molar equivalents of a tertiary amine such as triethylamine or N,N-diisopropylethylamine in a suitable solvent such as acetone, tetrahydrofuran, dimethylformamide, dichloromethane, and the like, at temperatures ranging from room temperature to the reflux temperature of the solvent to produce the corresponding arylamino-tert-butyl-carbamate.
Nitrobenzene intermediates that are ultimately converted to amines 2 and 5 by methods shown above in Methods 1A-1G may be prepared in accordance with
Methods 4A, 4C, 4E-4F.
Referring to Methods 4A, 4C, and 4E-4H, the nitrobenzene intermediates which arc ultimately converted into amines 2, R, and R, are defined above and R , R,, and/or R, are defined as alkoxy, thioalkoxy, alkylsulfenyl, alkylsulfinyl, and dialkylamino may be prepared by the nucleophilic displacement of appropriately substituted 2-, 4-, and/or 6-fluoro-, chloro-, bromo-, iodo-, trifluoromethylsuifonyl-, or (4-methylphenyl)sulfonyl-substituted nitrobenzenes by methods which include the following:

Claims (1)

  1. gp - 150 - CLAIMS What is claimed: LL A compound of the formula: Ra 5 Ro 10 gy SH o, GB Rz Ri Rit Riz 1 wherein
    R,-R, are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms,
    alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 carbon members, aryl, heteroaryl,
    halogen, -CN, -NO,, -CO,R,, -COR,, -OR,, -SR,, -SOR, -SOR,,
    -CONRR,, -NRN(RR,), -N(R,R,) or W-Y-(CH,),-Z provided that at least one of R,-R, is not hydrogen; or R, and R, or R, and R,, taken together form a 3 to 7 membered heterocycloalkyl or 3 to 7 membered heteroaryl;
    R, and R, are independently hydrogen, alkyl of 1 to 6 carbon atoms,
    perhaloalkyl of 1 to 6 carbon atoms, or aryl;
    R, is hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 members, aryl or heteroaryl, or
    R, and R,, taken together may form a 3 to 7 membered heterocycloalkyl;
    R,-R,, are independently hydrogen, alkyl of 1 to 4 carbon atoms, perhaloalkyl of 1 to 4 carbon atoms, halogen. alkoxy of 1 to 4 carbon atoms, or
    : cyano, or R, and R,, or R | and R,, may be taken together to form aryl of 5 10 7 carbon atoms; provided that at least one of R, is not hydrogen;
    Wis O, NR, or is absent,
    Y is -(CO)- or -(CO,)-, or is absent; Z is alkyl of 1 to 4 carbon atoms, -CN, -CO,R,, COR, -CONR,R,, -OCOR,, -NR,COR,, -OCONR,, -OR,, -SR, -SOR,, -SO,R,, SR6N(R7RS), -N(R,R,) or phenyl; G is a monocyclic heteroaryl; X is a bond, -NH, alkyl of 1 to 6 carbon atoms, alkenyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or thioalkyl of 1 to 6 carbon atoms, alkylamino of 1 to 6 carbon atoms, or (CH)J; J is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or benzyl; and n is an integer from 1 to 6, or pharmaceutical salts thereof.
    2. A compound of Claim 1 wherein R, through R are independently, hydrogen alkyl of 1 to 6 carbon atoms, halogen, perhaloalkyl of 1 to 6 carbon atoms, OR, or N(R,R,).
    3. A compound of Claim 1 wherein R,, R, and R; are hydrogen and R, and R, are independently, halogen or CF,.
    4. A compound of Claim 1 wherein R, R, and R, are hydrogen and R, and R, are independently, halogen or CF.
    5. A compound of Claim 1 wherein G is thiazolyl, thiadiazolyl, oxazolyl or fturyl
    6. A compound of Claim 1 wherein G is furyl.
    7. A compound of Claim 1 wherein R,-R_. are independently, hydrogen, halogen, methyl, methoxy and cyano.
    8. A compound of Claim 1 wherein X is a bond.
    9. A compound of Claim | wherein X is straight chain alkyl.
    10. A compound of Claim 1 wherein X is alkyl of 1 to 4 carbon atoms. 1L A compound of Claim 1 selected from: Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 2,5-dimethoxy-phenyl }-amide, Furan-2-carboxylic acid {4-{3-(5-chloro-2,4-dimethoxy-phenyl)-thiourcidoj- 3-trifluoromethyl-phenyl }-amide, Furan-2-carboxylic acid {3-chloro-4-[3-(5-chloro-2,4-dimethoxy-phenyl)- thioureido]-phenyl }-amide, Furan-2-carboxylic acid {5-chloro-4-{3-(5-chloro-2,4-dimethoxy-phenyl)- thioureido}-2-methyl-phenyl }-amide, Furan-2-carboxylic acid {5-chloro-4-[3-(5-chloro-2.4-dimethoxy-phenyl)- thiourcido]-2-hydroxy-phenyl }-amide, Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 3-cyano-phenyl}-amide, Furan-2-carboxyiic acid {4-{3-(5-chioro-2,4-dimethoxy-phenyl)-thioureido}- 3-methyl-phenylt-amide, Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 2-methoxy-5-methyl-phenyl}-amide. Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 3-methoxy-phenyl}-amide, Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimcthoxy-phenyl)-thioureido]- 2-tritfluoromethyl-phenyl }-amide. Furan-2-carboxylic acid {2-chloro-4-[3-(5-chloro-2,4-dimethoxy-phenyl)- thiourcido}-phenyl}-amide, Furan-2-carboxylic acid {4-{3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido}- 2-cyano-phenyl}-amide, 5-[3-(5-Chloro-2.4-dimethoxy-phenyl)-thioureido]}-2-[(turan-2-carbonyl)- amino}-benzoic acid, Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thiourcido|- 2-phenylcarbamoyl-phenyl }-amide,
    Furan-2-carboxylic acid {2-benzoyl-4-[3-(5-chloro-2.4-dimethoxy-phenyl)- thioureido]-phenyl }-amide, Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 2-methyl-phenyl }-amide, Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- naphthalen-1-yl }-amide; and Furan-2-carboxylic acid {4-[3-(5-chloro-2,4-dimethoxy-phenyl)-thioureido]- 2-methoxy-phenyl }-amide, or a pharmaceutical salt thereof.
    12. A pharmaceutical composition comprising a compound of the formula: Rs 5 Rg 10 gy SHUR BV : R: Ry Run Rp 1 wherein R-R, are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 carbon members, aryl, heteroaryl, halogen, -CN, -NO,, -CO,R,, -COR,, -OR, -SR, -SOR, -SO,R,, -CONRR,, -NR,N(R R,), -N(RR,) or W-Y-(CH,) -Z provided that at least one of R-R; is not hydrogen; or R, and R, or R; and R, taken together form a 3 to 7 membered heterocycloalkyl or 3 to 7 membered heteroaryl; R, and R, are independently hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, or aryl; A monocyclicR, is hydrogen, alkyl of | to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 members, aryl or heteroaryl, or R, and R,, taken together may form a 3 to 7 membered heterocycloalkyl;
    R,-R,, are independently hydrogen. alkyl of I to 4 carbon atoms, perhaloalky] of 110 4 carbon atoms. halogen. alkoxy of 1 to 4 carbon atoms, or cyano, or R, and R,, or R,, and R, may be taken together to form aryl of 5to 7 carbon atoms; provided that at least one of R,-,. is not hydrogen;
    W is O, NR, or is absent;
    Y 1s -(CO)- or -(CO,)-, or is absent;
    Zisalkyl of 1 to 4 carbon atoms. -CN.-CO,R, COR. -CONR,R,, -OCOR,, -NR,COR,, -OCONR,, -OR,, -SR,, -SOR, -SO,R,, SRN(RR,),
    -N(R,R,) or phenyl;
    (1s a monocyclic heteroaryl:
    X 1s a bond, -NH, alkyl! of | © 6 carbon atoms. alkenyl of | to 6 carbon atoms, alkoxy of | to 6 carbon atoms, or thioalkyl of 1 to 6 carbon atoms, alkylamino of 1 to 6 carbon atoms, or (CH)J;
    J is alkyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or benzyl; and n 1s an integer from | to 6,
    or pharmaceutical saits thereof; and a pharmaceutically acceptable carrer or diluent. {3 A mcthod of inhibiting the replication of a herpes virus comprising contaciing a compound of the formula: Rs Rs Re Rio Ss O pedo Ls Ra Ri Ray Re wherein R,-R; are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms. alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 carbon members, aryl, heteroaryl, halogen, -CN, -NO,, -COR,. -COR,, -OR,, -SR,, -SOR, -SO.R,.
    -CONR,R,, -NRN(RR,), -N(R R,) or W-Y-(CH,),-Z provided that at least one of R-R, is not hydrogen; or R. and R, or R, and R,, taken together form a 3 to 7 membered heterocycloalkyl or 3 to 7 membered heteroaryl; R, and R, are independently hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, or aryl; R, is hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 members, aryl or heteroaryl, or R, and R,, taken together may form a 3 to 7 membered heterocycloalkyl; R,-R,, are independently hydrogen, alkyl of 1 to 4 carbon atoms, perhaloalkyl of 110 4 carbon atoms, halogen, alkoxy of 1 10 4 carbon atoms, or cyano, or R; and R or R,, and R,, may be taken together to form aryl ’ of 5 to 7 carbon atoms; provided that at least one of R,-, is not hydrogen; ‘ W is O, NR,, or is absent; Y is -(CO)- or -(CO,)-, or is absent; Z is alkyl of 1 to 4 carbon atoms, -CN, -CO.,R,, COR, -CONRR,, -OCOR,, -NR,COR,, -OCONR,, -OR,, -SR,, -SOR,, -SO,R,, SRN(RR,), -N(R,R,) or phenyl; G is a monocyclic heteroaryl; X is a bond, -NH, alkyl of 1 to 6 carbon atoms, alkenyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or thioalkyl of 1 to 6 carbon atoms, alkylamino of 1 to 6 carbon atoms, or (CH)J; J is alkyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or benzyl; and n is an integer from 1 to 6, or pharmaceutical salts thereof, with a herpes virus.
    14. The method of Claim 13 wherein the herpes virus is human cytomegalovirus.
    15. The method of Claim 13 wherein the herpes virus is herpes simplex virus.
    16. The method of Claim 13 where the herpes virus is varicella zoster virus.
    17. A method of treating a patient suffering from a herpes virus infection comprising administering to the patient in need thereof a therapeutically effective S amount of a compound having the formula: R4 5 Rg 10 gy SHS Bo, OVE 5 R, Ry Ry; Ri 1 wherein R,-R, are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, i perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 1) carbon atoms, heterocycloalkyl of 3 to 10 carbon members, aryl, heteroaryl, halogen, -CN, -NO,, -CO,R,, -COR_, -OR,, -SR,, -SOR,, -SO.R,, -CONR,R,. -NR,N(R R}) -N(R R,) or W-Y-(CH,) -Z provided that at least one of R -R, is not hydrogen; or R, and R, or R, and R,, taken gether form a 3 to 7 membered heterocycloalkyl or 3 to 7 membered heteroaryl; R, and R, are independently hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, or aryl; R, is hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 members, aryl or heteroaryl, or R, and R,, taken together may form a 3 to 7 membered heterocycloalkyl: R,-R,.are independently hydrogen, alkyl of 1 to 4 carbon atoms, perhaloalkyl of 1 to 4 carbon atoms, halogen, alkoxy of 1 to 4 carbon atoms, or cyano, or R; and Ror R,, and R,, may be taken together to form aryl of 5107 carbon atoms; provided that at least one of R, , is not hydrogen; Wis O, NR, or is absent:
    Y is -(CO)- or -(CO,)-, or is absent; Z is alkyl of 1 to 4 carbon atoms, -CN, -CO,R,, COR, -CONRR,, -OCOR,, -NR,COR,, -OCONR,, -OR,, -SR,, -SOR,, -SO,R,, SRN(RR,), -N(R,R,) or phenyl; G is a monocyclic heteroaryl; X is a bond, -NH, alkyl of 1 to 6 carbon atoms, alkenyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or thioalkyl of 1 to 6 carbon atoms, alkylamino of 1 to 6 carbon atoms, or (CH)J; J is alkyl of 2 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or benzyl; and n is an integer from 1 to 6, or pharmaceutical salts thereof. . 18. The method of Claim 17 wherein the herpes virus is human cytomegalovirus.
    19. The method of Claim 17 wherein the herpes virus is herpes simplex virus.
    20. The method of Claim 17 where the herpes virus is varicella zoster virus.
ZA200104322A 1998-12-09 2001-05-25 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group. ZA200104322B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20816498A 1998-12-09 1998-12-09

Publications (1)

Publication Number Publication Date
ZA200104322B true ZA200104322B (en) 2002-10-25

Family

ID=22773466

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200104322A ZA200104322B (en) 1998-12-09 2001-05-25 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group.

Country Status (14)

Country Link
EP (1) EP1144399A3 (en)
JP (1) JP2002533301A (en)
KR (1) KR20010086091A (en)
CN (1) CN1367785A (en)
AU (1) AU2353900A (en)
BR (1) BR9916043A (en)
CA (1) CA2351690A1 (en)
CZ (1) CZ20012063A3 (en)
EA (1) EA200100639A1 (en)
HU (1) HUP0203405A2 (en)
IL (1) IL143263A0 (en)
NO (1) NO20012835L (en)
WO (1) WO2000034261A2 (en)
ZA (1) ZA200104322B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
KR20070007759A (en) * 2003-07-10 2007-01-16 아칠리온 파르마세우티칼스 인코포레이티드 Substituted arylthiourea derivatives useful as inhibitors of viral replication
DE102004015007A1 (en) 2004-03-26 2005-10-13 Bayer Healthcare Ag Substituted imidazoles
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
DE102005008183A1 (en) 2005-02-23 2006-08-31 Bayer Healthcare Ag New heterocyclylamide-substituted imidazole compounds useful to treat or prevent viral infections
EP2077995B1 (en) 2006-11-02 2012-02-08 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
WO2014070979A1 (en) * 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
US9284310B2 (en) 2012-11-03 2016-03-15 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
CN112807294B (en) * 2019-11-18 2023-09-05 武汉大学 Application of acyl thiourea compound in preparation of medicines for treating or preventing herpes simplex virus type I infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519808A (en) * 1997-04-10 2001-10-23 ファルマシア・アンド・アップジョン・カンパニー Polyaromatic antibacterial composition

Also Published As

Publication number Publication date
EP1144399A3 (en) 2002-09-11
IL143263A0 (en) 2002-04-21
CZ20012063A3 (en) 2001-10-17
AU2353900A (en) 2000-06-26
EP1144399A2 (en) 2001-10-17
JP2002533301A (en) 2002-10-08
HUP0203405A2 (en) 2003-02-28
WO2000034261A3 (en) 2002-01-31
NO20012835D0 (en) 2001-06-08
WO2000034261A2 (en) 2000-06-15
NO20012835L (en) 2001-07-19
CA2351690A1 (en) 2000-06-15
EA200100639A1 (en) 2002-06-27
KR20010086091A (en) 2001-09-07
BR9916043A (en) 2001-12-04
CN1367785A (en) 2002-09-04

Similar Documents

Publication Publication Date Title
EP0243670B1 (en) Purine and pyrimidine compounds and their use as anti-viral agents
DK168323B1 (en) Use of certain pyrimidine nucleosides for the manufacture of a drug for VZV infections; novel pyrimidine nucleosides, such compounds for use in human therapy, and methods for the preparation of the compounds
ZA200104142B (en) Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses.
ZA200104322B (en) Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group.
RU2642463C2 (en) Cyclopropane carboxylate ethers of purine analogues
DK159683B (en) 9- (4-HYDROXYBUTYL) -GUANINE DERIVATIVE, PHARMACEUTICAL PREPARATION CONTAINING SUCH A COMPOUND AND USE OF IT FOR THE PREPARATION OF A MEDICINE
CN113278040B (en) Preparation method of 5' -isobutyryl-N4-hydroxycytidine
CN113307833A (en) Preparation method of N4-hydroxycytidine
ZA200104376B (en) Alpha-methybenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine groups.
ZA200104373B (en) Thiourea inhibitors of herpes viruses.
CA2753825C (en) Process for preparing substituted pyrimidine antiviral compound
Shigeta et al. Synthesis and antiherpesvirus activities of 5-alkyl-2-thiopyrimidine nucleoside analogues
TWI385172B (en) Novel compounds
ZA200104318B (en) Thiourea inhibitors of herpes viruses.
DE69919023T2 (en) THIROUS INHIBITORS OF HERPES VIRUS
US6022876A (en) L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
WO2022165162A1 (en) Selective cyclin-dependent kinase inhibitors and methods of therapeutic use thereof
EP0168003B1 (en) Oxindol compounds, compositions containing same and processes for preparing same
PH26589A (en) Esters of 5-propynyl pyrimidine nucleosides
US20040157900A1 (en) Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus
CN115322120A (en) Small molecule compound and its preparation method application of DHODH mediated disease medicine
JPH06211864A (en) N1-substituted 1h-1,2,3-triazolo(4,5-d)pyrimidine, its preparation, and its use as antiviral agent